stoxline Quote Chart Rank Option Currency Glossary
Spruce Biosciences, Inc. (SPRB)
1.3801  -0.02 (-1.42%)    11-29 10:18
Open: 1.35
High: 1.429
Volume: 3,542
Pre. Close: 1.4
Low: 1.35
Market Cap: 56(M)
Technical analysis
2023-11-29 10:19:46 AM
Short term     
Mid term     
Targets 6-month :  1.66 1-year :  1.94
Resists First :  1.42 Second :  1.66
Pivot price 1.26
Supports First :  1.17 Second :  1
MAs MA(5) :  1.39 MA(20) :  1.22
MA(100) :  1.89 MA(250) :  2.05
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  96.7 D(3) :  94.8
RSI RSI(14): 59.2
52-week High :  3.56 Low :  0.95
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SPRB ] has closed below upper band by 21.8%. Bollinger Bands are 33.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.41 - 1.42 1.42 - 1.42
Low: 1.35 - 1.36 1.36 - 1.37
Close: 1.39 - 1.4 1.4 - 1.41
Company Description

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Headline News

Mon, 13 Nov 2023
Spruce Biosciences Reports Third Quarter 2023 Financial Results ... - Business Wire

Thu, 02 Nov 2023
Spruce Biosciences to Participate in the Jefferies London Healthcare Conference - Yahoo Finance

Fri, 08 Sep 2023
S&P Futures Tick Lower as Interest Rate Uncertainty Weighs on ... - Nasdaq

Thu, 25 May 2023
Spruce Biosciences Appoints Percival Barretto-Ko to Board of ... - Business Wire

Thu, 23 Feb 2023
Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400% - Penny Stocks

Thu, 09 Feb 2023
Spruce Biosciences Announces $53.6 Million Private Placement ... - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 41 (M)
Shares Float 13 (M)
Held by Insiders 0.4 (%)
Held by Institutions 91.7 (%)
Shares Short 35 (K)
Shares Short P.Month 38 (K)
Stock Financials
EPS -1.49
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.09
Profit Margin 0 %
Operating Margin -444.5 %
Return on Assets (ttm) -31.8 %
Return on Equity (ttm) -60 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.17
EBITDA (p.s.) -1.3
Qtrly Earnings Growth 0 %
Operating Cash Flow -34 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.97
PEG Ratio 0
Price to Book value 0.68
Price to Sales 8.07
Price to Cash Flow -1.73
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android